Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) closed at $22.8 in the last session, up 1.11% from day before closing price of $22.55. In other words, the price has increased by $1.11 from its previous closing price. On the day, 1.56 million shares were traded. CPRX stock price reached its highest trading level at $22.8501 during the session, while it also had its lowest trading level at $22.195.
Ratios:
We take a closer look at CPRX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.95. For the most recent quarter (mrq), Quick Ratio is recorded 6.40 and its Current Ratio is at 6.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Robert W. Baird on February 04, 2025, initiated with a Outperform rating and assigned the stock a target price of $28.
On November 18, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $35.
On March 14, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $27.Citigroup initiated its Buy rating on March 14, 2024, with a $27 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 26 ’25 when Del Carmen Jeffrey sold 10,983 shares for $23.33 per share. The transaction valued at 256,244 led to the insider holds 3,962 shares of the business.
Del Carmen Jeffrey bought 10,983 shares of CPRX for $256,247 on Nov 26 ’25. On Nov 12 ’25, another insider, Elsbernd Brian, who serves as the Officer of the company, bought 40,000 shares for $22.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 2802402304 and an Enterprise Value of 2115399424. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.30, and their Forward P/E ratio for the next fiscal year is 12.77. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.85 while its Price-to-Book (P/B) ratio in mrq is 3.05. Its current Enterprise Value per Revenue stands at 3.659 whereas that against EBITDA is 7.133.
Stock Price History:
The Beta on a monthly basis for CPRX is 0.72, which has changed by 0.056701064 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, CPRX has reached a high of $26.58, while it has fallen to a 52-week low of $19.05. The 50-Day Moving Average of the stock is 4.46%, while the 200-Day Moving Average is calculated to be 3.28%.
Shares Statistics:
According to the various share statistics, CPRX traded on average about 1.37M shares per day over the past 3-months and 1127350 shares per day over the past 10 days. A total of 123.26M shares are outstanding, with a floating share count of 110.81M. Insiders hold about 9.84% of the company’s shares, while institutions hold 80.96% stake in the company. Shares short for CPRX as of 1764288000 were 7936656 with a Short Ratio of 5.77, compared to 1761868800 on 7923703. Therefore, it implies a Short% of Shares Outstanding of 7936656 and a Short% of Float of 8.2399994.
Earnings Estimates
The market rating of Catalyst Pharmaceuticals Inc (CPRX) is currently shaped by the ongoing analysis conducted by 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.59, with high estimates of $0.64 and low estimates of $0.53.
Analysts are recommending an EPS of between $2.7 and $2.11 for the fiscal current year, implying an average EPS of $2.5. EPS for the following year is $2.58, with 4.0 analysts recommending between $2.7 and $2.47.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $141.49M. It ranges from a high estimate of $149.64M to a low estimate of $136.14M. As of. The current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $141.82MFor the next quarter, 7 analysts are estimating revenue of $142.4M. There is a high estimate of $144.18M for the next quarter, whereas the lowest estimate is $139.5M.
A total of 7 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $586.02M, while the lowest revenue estimate was $572.52M, resulting in an average revenue estimate of $577.87M. In the same quarter a year ago, actual revenue was $491.73MBased on 7 analysts’ estimates, the company’s revenue will be $619.51M in the next fiscal year. The high estimate is $633.67M and the low estimate is $595.52M.
